US Patent

US8415332 — Methods of hormonal treatment utilizing ascending-dose extended cycle regimens

Formulation · Assigned to Teva Womens Health Inc · Expires 2029-03-11 · 3y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of hormonal treatment using specific regimens that combine estrogen and progestin for extended periods.

USPTO Abstract

The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered to a female to provide contraceptive and non-contraceptive benefits.

Drugs covered by this patent

Patent Metadata

Patent number: US8415332
Jurisdiction: US
Classification: Formulation
Expires: 2029-03-11
Drug substance claim: No
Drug product claim: Yes
Assignee: Teva Womens Health Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.